NasdaqGM:RDNT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. More Details


Snowflake Analysis

Moderate growth potential with imperfect balance sheet.


Similar Companies

Share Price & News

How has RadNet's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RDNT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.3%

RDNT

1.7%

US Healthcare

0.4%

US Market


1 Year Return

4.2%

RDNT

22.7%

US Healthcare

17.8%

US Market

Return vs Industry: RDNT underperformed the US Healthcare industry which returned 22.7% over the past year.

Return vs Market: RDNT underperformed the US Market which returned 17.8% over the past year.


Shareholder returns

RDNTIndustryMarket
7 Day-2.3%1.7%0.4%
30 Day9.7%10.8%6.1%
90 Day6.3%7.6%8.9%
1 Year4.2%4.2%24.3%22.7%20.5%17.8%
3 Year50.3%50.3%37.2%31.4%42.3%32.9%
5 Year128.2%128.2%66.3%54.1%84.2%63.4%

Price Volatility Vs. Market

How volatile is RadNet's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is RadNet undervalued compared to its fair value and its price relative to the market?

5.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: RDNT ($15.93) is trading above our estimate of fair value ($10.7)

Significantly Below Fair Value: RDNT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RDNT is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: RDNT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RDNT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RDNT is overvalued based on its PB Ratio (5.6x) compared to the US Healthcare industry average (3.2x).


Next Steps

Future Growth

How is RadNet forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

92.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RDNT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: RDNT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RDNT's is expected to become profitable in the next 3 years.

Revenue vs Market: RDNT's revenue (8.5% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: RDNT's revenue (8.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RDNT's Return on Equity is forecast to be low in 3 years time (9.9%).


Next Steps

Past Performance

How has RadNet performed over the past 5 years?

9.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RDNT is currently unprofitable.

Growing Profit Margin: RDNT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RDNT is unprofitable, but has reduced losses over the past 5 years at a rate of 9.9% per year.

Accelerating Growth: Unable to compare RDNT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RDNT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.2%).


Return on Equity

High ROE: RDNT has a negative Return on Equity (-2.22%), as it is currently unprofitable.


Next Steps

Financial Health

How is RadNet's financial position?


Financial Position Analysis

Short Term Liabilities: RDNT's short term assets ($247.5M) do not cover its short term liabilities ($382.4M).

Long Term Liabilities: RDNT's short term assets ($247.5M) do not cover its long term liabilities ($1.1B).


Debt to Equity History and Analysis

Debt Level: RDNT's debt to equity ratio (290%) is considered high.

Reducing Debt: RDNT's debt to equity ratio has reduced from 5090.9% to 290% over the past 5 years.

Debt Coverage: RDNT's debt is well covered by operating cash flow (28.3%).

Interest Coverage: RDNT is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is RadNet current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RDNT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RDNT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RDNT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RDNT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RDNT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

13.8yrs

Average management tenure


CEO

Howard Berger (74 yo)

33.75yrs

Tenure

US$1,910,570

Compensation

Dr. Howard G. Berger, M.D., serves as the President and Chief Financial Officer of Image Medical Corporation. Dr. Berger has been the Chief Executive Officer and President at RadNet, Inc. and its predecess ...


CEO Compensation Analysis

Compensation vs Market: Howard's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD2.94M).

Compensation vs Earnings: Howard's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Howard Berger
Chairman33.75yrsUS$1.91mno data
Mark Stolper
Executive VP & CFO16.25yrsUS$1.11m0.18%
$ 1.5m
Norman Hames
President & COO of Western Operationsno dataUS$1.17m0.98%
$ 8.1m
Stephen Forthuber
President & COO of Eastern Operations3.42yrsUS$1.18m0.92%
$ 7.5m
Ranjan Jayanathan
Chief Information Officer & GM of eRAD - Radiology Information Technology Divisionno datano datano data
Laura Foster
Senior Vice President of Compliance & Regulatory Affairs3.58yrsno datano data
David Katz
Executive VP & General Counsel0.58yrno data0.048%
$ 398.2k
Ruth Wilson
Senior VP of Human Resources & Director1.17yrsno data0.043%
$ 350.5k
John Crues
VP, Medical Director & Director20.75yrsUS$555.87k0.83%
$ 6.8m
Michael Murdock
Executive VP & Chief Development Officer13.75yrsno data0.20%
$ 1.6m
Derek Bomar
Senior VP & Director of Materials & Asset Management17.75yrsno datano data
Deborah Saly
Senior VP & Deputy General Counselno datano datano data

13.8yrs

Average Tenure

59yo

Average Age

Experienced Management: RDNT's management team is seasoned and experienced (13.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Howard Berger
Chairman33.75yrsUS$1.91mno data
Ruth Wilson
Senior VP of Human Resources & Director1.17yrsno data0.043%
$ 350.5k
John Crues
VP, Medical Director & Director20.75yrsUS$555.87k0.83%
$ 6.8m
Marvin Cadwell
Independent Director13.75yrsUS$191.50k0.55%
$ 4.5m
David Swartz
Lead Independent Director9.75yrsUS$220.50k0.36%
$ 3.0m
Lawrence Levitt
Independent Director15.75yrsUS$200.50k0.34%
$ 2.8m
Laura Jacobs
Director0.75yrno data0.014%
$ 117.7k

11.8yrs

Average Tenure

72yo

Average Age

Experienced Board: RDNT's board of directors are seasoned and experienced ( 11.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RDNT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.


Top Shareholders

Company Information

RadNet, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: RadNet, Inc.
  • Ticker: RDNT
  • Exchange: NasdaqGM
  • Founded: 1985
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$821.586m
  • Shares outstanding: 51.57m
  • Website: https://www.radnet.com

Number of Employees


Location

  • RadNet, Inc.
  • 1508, 1510 and 1516 Cotner Avenue
  • Los Angeles
  • California
  • 90025
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RDNTNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 1990
PQIADB (Deutsche Boerse AG)YesCommon StockDEEUROct 1990

Biography

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 05:19
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.